TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT06566495

Intervention type: DEVICE
Intervention: collection of microbiological material from reusable tourniquets
Description: Microbiological analysis~The material was collected in each group in the same way.

Intervention type: DEVICE
Intervention: collection of microbiological material from reusable tourniquets
Description: Microbiological analysis~The material was collected in each group in the same way.

Intervention type: DEVICE
Intervention: collection of microbiological material from reusable tourniquets
Description: Microbiological analysis~The material was collected in each group in the same way.
Study: NCT06564337

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Surveyed zirconia crown
Description: Patient recruitment will be from the patient population that presents to the undergraduate dental clinic requiring removable dental prosthesis (RPD) to replace missing teeth. Selection of abutment teeth for zirconia surveyed crowns will be similar to that currently utilized when selecting RPD abutments to be restored with either porcelain fused to metal or full metal surveyed crowns for tissue and tooth supported RPD's.
Study: NCT04682561

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Supportive Trauma Exposure Preparation Program
Description: The Supportive Trauma Exposure Preparation Program is based on the theory that the ability to set compassionate boundaries will enhance acceptance of the reality of trauma in the workplace, and will also increase the cognitive/emotional/physical energy needed to engage in adaptive emotional strategies in response to trauma exposure. Therefore, the goal of therapy is to learn to set compassionate boundaries and engage with oneself and others from a perspective of self-empowerment and acceptance of life events. Concepts and skills will be addressed through the following modules: 1) understanding of trauma and its effects, 2) personal rights and boundaries, 3) emotional literacy, 4) distress tolerance and emotion regulation skills building, 5) communication skills building, 6) self-compassion and acceptance, and 7) enhancing self-care.
Study: NCT06542003

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Movin' and Groovin' for Wellness
Description: Movin' and Groovin' for Wellness (MGW) is a 10-week program consisting of facilitated drumming and dancing sessions. The sessions include guided activities involving drumming, dancing, and group improvisation. Each session lasts approximately 1.5 hours, with activities designed to improve mental well-being, enhance social connections, and foster creative expression. The sessions are guided by professional facilitators.
Study: NCT06199973

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SHR-A1811
Description: SHR-A1811(4.8 mg/kg) was administered intravenously on the first day of each cycle, once every 3 weeks (Q3W)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TAS-102, Regorafenib , Fruquintinib
Description: physician choiced treatment,include: TAS-102(35 mg/m2, maximum 80 mg per dose), twice daily (BID) , once every 4 weeks (Q4W) , up to 3 years; or Regorafenib 160mg, once daily (QD) , once every 4 weeks (Q4W) , up to 3 years; or Fruquintinib 5mg once daily (QD) , once every 4 weeks (Q4W) , up to 3 years.
Study: NCT04760574

Intervention type: DIAGNOSTIC_TEST
Intervention: Testosterone
Description: Serum total testosterone and free testosterone level

Intervention type: DIAGNOSTIC_TEST
Intervention: Testosterone
Description: Serum total testosterone and free testosterone level
Study: NCT06338800

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: One session exposure with Virtual Reality
Description: Participants will receive one session exposure with virtual reality from their therapists.
Study: NCT06061302

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Immediate yoga intervention
Description: Subjects will complete 12 consecutive weeks of weekly 40 minute guided mindful yoga weeks 1-12.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Delayed yoga intervention
Description: Subjects will complete 12 consecutive weeks of weekly 40 minute guided mindful yoga weeks 13-24.
Study: NCT06012175

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Melatonin
Description: One 3 mg melatonin tablet every night before bedtime for 12 weeks

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: One placebo tablet, having an identical appearance to the melatonin tablet, every night before bedtime for 12 weeks
Study: NCT04994366

Intervention type: OTHER
Intervention: Thank you card
Description: A card thanking the patient for choosing NYU and entrusting us with their care. The card notifies the patient that they may receive a patient satisfaction survey after discharge.
Study: NCT05497843

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Chiauranib
Description: 50mg, orally once daily
Study: NCT05859347

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Repetitive Transcranial Magnetic Stimulation
Description: rTMS is a non-invasive neuromodulatory technique that applies alternating magnetic fields to the scalp to induce electric currents in localized cortical tissue. The intervention (LF or HF rTMS) will be administered daily 5 days/week for 4 weeks, using the MagVenture MMC-140 circular coil, with the brain regions targeted as the bilateral prefrontal cortex and the insula.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Repetitive Transcranial Magnetic Stimulation
Description: rTMS is a non-invasive neuromodulatory technique that applies alternating magnetic fields to the scalp to induce electric currents in localized cortical tissue. The intervention (LF or HF rTMS) will be administered daily 5 days/week for 4 weeks, using the MagVenture MMC-140 circular coil, with the brain regions targeted as the bilateral prefrontal cortex and the insula.
Study: NCT04651218

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: exericse
Description: participants perform aerobic exercise until they expend 500 kcal
Study: NCT06413589

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: SMOF lipid 20%
Description: Drug: SMOF lipid 20% SMOF 20%, a blend of soybean oil, medium-chain triglycerides, olive oil, and fish oil, is a new lipid emulsion product that was provided as a bolus dose of 1.5ml/kg for one hour, followed by a maintenance dose of 6 ml/kg for a period of four hours to the active comparator group

Intervention type: OTHER
Group type: OTHER
Intervention: standard treatment for clozapine toxicity
Description: Hypotension was initially treated with isotonic crystalloid; vasopressors were utilised if intravenous fluids failed to restore the hypotension. This was in the form of norepinephrine with a dose of 0.05 μg/kg/min and titrated till reaching the goal mean arterial pressure (\>65 mmHg) \[29\].~Those experiencing seizures due to CBZ overdose were treated with benzodiazepines (diazepam) at a dose of 10-20 mg. Benzodiazepines are considered allosteric modulators of the gamma-aminobutyric acid channel.~MDAC (50 grammes every six hours) was given to all patients in the current study. Those with severe poisoning were given the MDAC after securing the airway with a cuffed endotracheal tube
Study: NCT05340517

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: video-assisted rib planting
Description: Give the patient intercostal nerve block and laryngeal mask anesthesia, after that, put the patient in lateral position. Make a 4-6cm posterolateral incision along the lower edge of the scapula，sever latissimus dorsi and serratus anterior and reach the rib surface. Lift the scapula with the abdominal retractor (or xiphoid retractor), Free adhesion tissue inside the scapula and put in the thoracoscopic lens. Free the tissue of the upper and lower edges of the ribs carefully, reset ribs and insert rib plate, which is fixed by 90° electric drill and locking screw.
Study: NCT05013892

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: NTS-WBRT (normal tissue sparing whole brain radiation therapy)
Description: Radiation

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Memantine
Description: Capsule, taken orally
Study: NCT05768308

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Internet CBT-UP intervention iCBT-UP
Description: The self-helped internet intervention for students experiencing emotional difficulties, especially adjustment disorder. This intervention is based on transdiagnostic cbt principles - unified protocol (Barlow et al., 2018). It is a modular intervention consisting of six modules teaching different skills of dealing with emotions. Intervention is interactive and contains of video materials, quizes, texts and audio materials.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Internet Progressive Muscle Realxation Training (iPMR)
Description: Participants from the active control group will receive progressive muscle relaxation training (iPMR) (Bernstein, Borkovec, Hazlett-Stevens, 2000). It is also a modular intervention and, similar to the i-cbt condition, consists of 5 modules. During the intervention, participants learn how to progressively tighten and relax different muscle groups.The first module is planned for two weeks and the rest of them for one week each. Intervention consists of video materials and audio guided relaxations. Participants are encouraged to train these relaxations once a day.
Study: NCT04719585

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Duloxetine vs. Opioid
Description: Prior to discharge, the drug is prescribed for a total of 6 weeks by dividing the duloxetine-administered group and the opioid-administering group, respectively. The administration period of duloxetine or opioid is 6 weeks. The follow-up periods for out-patient clinic are 2 weeks, 6 weeks, 3 months, 6 months, and 1 year after the TKA surgery. During the follow-up period, NSAIDs will be prescribed the same in both groups. As an additional rescue medication, 650 mg of acetaminophen will be allowed to use up to 2g per day.
Study: NCT05106023

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Temozolomide
Description: SHR-1701 combined with temozolomide
Study: NCT04719585

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Duloxetine vs. Opioid
Description: Prior to discharge, the drug is prescribed for a total of 6 weeks by dividing the duloxetine-administered group and the opioid-administering group, respectively. The administration period of duloxetine or opioid is 6 weeks. The follow-up periods for out-patient clinic are 2 weeks, 6 weeks, 3 months, 6 months, and 1 year after the TKA surgery. During the follow-up period, NSAIDs will be prescribed the same in both groups. As an additional rescue medication, 650 mg of acetaminophen will be allowed to use up to 2g per day.
Study: NCT06234345

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fluticasone 250mcg/Formoterol 12mcg/Glycopyrronium 25mcg
Description: Participants randomized to this group will receive 1 capsule per inhalation twice a day

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Comparator - Trimbow®
Description: Participants randomized to this group will receive 2 triggering twice a day
Study: NCT06535126

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CanProFem-AK
Description: Dosage form - vaginal suppositories (100 mg). Dosage regimen - single intravaginal administration of suppository. Vaginal suppositories are inserted as deeply as possible while the participant is lying down; the participant must remain in a horizontal position for 45 minutes after the administration. The total duration of volunteer participation in the study is one day. Medical observation (including gynaecological monitoring with vaginal bacterial swab test) of the subject condition after the drug administration will be carried out after 3, 6, 9, 12 and 24 hours. Repeated laboratory blood and urine tests will be performed after 24 hours. Participants of the study will be closely monitored for 24 hours after the initial administration of the drug to detect any immediate adverse events. If the subject experiences an immediate adverse event, appropriate treatment will be provided.
Study: NCT05015894

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NNC0480-0389
Description: A single dose of 18 mg NNC0480 0389 administered subcutaneously (under the skin).~Total duration of study participation for each participant is 38 to 66 days
Study: NCT05492136

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Additional margin coagulation
Description: After performing the hepatectomy the selected device should be applied onto the surgical margin following the protocol 3-4 s/cm2 of liver transection surface at maximum power output in order to perform an additional margin coagulation
Study: NCT05961293

Intervention type: DEVICE
Group type: OTHER
Intervention: NeuroGlove
Description: NeuroGlove is a non-invasive device that provides peripheral somatosensory stimulation to the hand of a stroke victim during acute, subacute, or chronic phases of a stroke. NeuroGlove provides sensory stimulation in the forms of pneumatic puffs of air. There is some early evidence that early peripheral sensory stimulation may improve neurological outcomes following an ischemic stroke.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: NeuroGlove
Description: NeuroGlove is a non-invasive device that provides peripheral somatosensory stimulation to the hand of a stroke victim during acute, subacute, or chronic phases of a stroke. NeuroGlove provides sensory stimulation in the forms of pneumatic puffs of air. There is some early evidence that early peripheral sensory stimulation may improve neurological outcomes following an ischemic stroke.
Study: NCT06381479

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: probiotics
Description: each capsule contains Lactiplantibacillus plantarum and Lacticaseibacillus paracasei, 2 caps daily use

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: The placebo capsule contains microcrystalline cellulose, 2 caps daily use.
Study: NCT06204159

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: TACE Catheters
Description: End Hole and TriNav catheters are FDA approved. This study is comparing the two for chemotherapy delivery during the TACE procedure.~This study will randomize which catheter is used for the first TACE procedure and the other catheter will be used for the second TACE procedure

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: TACE Catheters
Description: End Hole and TriNav catheters are FDA approved. This study is comparing the two for chemotherapy delivery during the TACE procedure.~This study will randomize which catheter is used for the first TACE procedure and the other catheter will be used for the second TACE procedure
Study: NCT05126199

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Time restricted eating
Description: Following a 3 day baseline dietary assessment using the Nutritics 'app', patients will immediately commence time-restricted eating on a 18:6 basis (18 hours fasting, 6 hours eating window) for 12 weeks.~Participants will consume all their meals within a daily 6-hour period of their choosing, and this may change according to patient's lifestyle and preference to reflect a real-world situation. Participants may eat ad libitum / according to appetite during the eating period. Participants will fast for 18 hours per day, consuming only plain water, unflavoured/unsweetened sparkling water, black breakfast tea or black coffee. Alcohol must not be consumed during fasting periods~Dietary intake will again be measured using the Nutritics 'app' midpoint through the 12-week period (week 6 +/- 1 week) and in the last week of the intervention (week 11/12).

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Normal ad libitum diet
Description: Following a 3-day baseline dietary assessment using the Nutritics 'app', participants with be directed to continue with their usual dietary intake without any time-related restrictions for 12 weeks. There will be no defined eating window and fasting or restrictions regarding types of food or drink consumed.~Dietary intake will again be measured using the Nutritics 'app' midpoint through the 12-week period (week 6 +/- 1 week) and in the last week of the intervention (week 11/12).
Study: NCT06646900

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Culturally adapted CBT (CaCBT) based guided self-help manual
Description: The intervention consists of seven modules including cognitive restructuring, problem solving, behavioural activation and conflict management. Three additional modules focus on interpersonal relationships, mental health wellbeing and self-care. Each module is delivered over one week. The intervention uses culturally appropriate stories, drawings, examples from local folklore and religious context to describe the concepts of CBT.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Standard CBT Manual
Description: The standard CBT manual will follow conventional CBT techniques without specific cultural adaptations
Study: NCT06107205

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: TTYP01
Description: 1 single oral dose of 90 mg TTYP01 (3 tablets of the test drugs, test formulation T)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Radicava
Description: 1 injection of 60 mg Radicava (reference drug R1, intravenous infusion of 60 mg administered over 60 minutes)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Radicava ORS
Description: 1 single oral dose of 105 mg/5 mL Radicava ORS (reference drug R2)
Study: NCT05374967

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Lifestyle intervention: Live with IBD
Description: A digital lifestyle intervention divided into two phases:~1. An intensive phase lasting six months~2. a facultative phase lasting six months~During the Intensive Phase, participants will receive regular counseling by a nutritionist and a lifestyle coach in groups of 25 people. Participants will also follow five online meetings focusing on either nutrition, exercise, sleep, and stress. In addition, participants will have 24/7 access to an online platform that contains additional information, challenges, recipes, and peer-support groups. Finally, during the facultative phase, participants can attend smaller group sessions for additional counseling by a nutritionist or a lifestyle coach; these sessions will be organized every six to 12 weeks.

Intervention type: OTHER
Group type: OTHER
Intervention: Control group
Description: The standard of care for patients with IBD suffering from chronic fatigue.
Study: NCT06148337

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: unhydrolyzed eggshell membrane
Description: an unhydrolyzed, minimally processed chicken eggshell membrane powder.

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: psyllium husk fiber powder
Study: NCT06228092

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: neostigmine/glycopyrrolate
Description: Anesthesia personnel will administer the drug as a bolus over 5 seconds in an intravenous catheter upon conclusion of anaesthesia with a TOF within the range from TOF count of 2 to a TOF ratio \< 0.60
Study: NCT06155825

Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: no intervention
Description: Group 4 will receive no intervention

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: nonnutritive suckling
Description: Group 1 will receive nonnutritive suckling

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: oral glucose 25%
Description: Group 2 will receive oral glucose 25%

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: facilitated tuckling
Description: Group 3 will undergo facilitated tuckling
Study: NCT06127979

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: core needle biopsy
Description: Pre-Endocrine Therapy core needle biopsy. The pre-treatment research biopsy will require a biopsy marker clip to document that the cancer lesion was biopsied

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: blood draw
Description: blood draw
Study: NCT05110625

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: preDIABE-TEXT
Description: Participants will receive text messages (three per week) in their mobile phones during six months.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: preDIABE-TEXT
Description: Participants will receive text messages (three per week) in their mobile phones during six months.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Online Education
Description: Primary healthcare workers will receive an online educacion about prediabetes. This intervention will aim at: 1) raising awareness about the importance of T2DM prevention; 2) increasing knowledge about effective strategies for diabetes prevention; 3) improving knowledge about brief counselling techniques; and, 4) enhancing communication skills.
Study: NCT04844294

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Brief Cognitive Behavioral Therapy (BCBT)
Description: BCBT is divided into three phrases. In phase I (5 sessions), the therapist conducts a detailed assessment of the patient's most recent suicidal episode or suicide attempt, identifies patient-specific factors that contribute to and maintain suicidal behaviors, provides a cognitive-behavioral conceptualization, collaboratively develops a crisis response plan, and teaches basic emotion regulation skills such as relaxation and mindfulness. In phase II (5 sessions), the therapist applies cognitive strategies to reduce beliefs and assumptions that serve as vulnerabilities to suicidal behavior. In phase III (2 sessions), a relapse prevention task is conducted.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Present-Centered Therapy (PCT)
Description: PCT includes (1) psychoeducation about the typical symptoms and features associated with suicidal thoughts and behaviors; (2) normalization of symptoms; (3) experience of receipt of support and feedback from a licensed professional; and (4) positive interpersonal interactions. PCT differs from BCBT in several key ways including less structure (i.e., patients are allowed to have more input into PCT session agendas) and no systematic training in behavioral or cognitive strategies for managing emotions and changing suicide-focused thoughts. PCT will be used as an active comparator because it is an empirically supported treatment for depression and PTSD that also reduces suicidal ideation (Bryan et al., 2016; Resick et al., 2017), but contains unique elements that distinguish the treatment from BCBT.
Study: NCT06228092

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sugammadex
Description: Anesthesia personnel will administer the drug as a bolus over 5 seconds in an intravenous catheter upon conclusion of anaesthesia with a TOF within the range from TOF count of 2 to a TOF ratio \< 0.60